Navigation Links
LaVoie Group Selected by Vaccine Developer, Profectus BioSciences, as Agency of Record
Date:4/29/2009

SALEM, Mass., April 29 /PRNewswire/ -- LaVoie Group, a life science-focused strategic communications agency, announced today that it has been selected as public relations agency of record by therapeutic vaccine development company, Profectus BioSciences, Inc.

Donna L. LaVoie, President & CEO of LaVoie Group, commented, "We are delighted to represent Profectus during an important stage in the company's clinical development. We look forward to working with them to communicate their message to appropriate investors, media, pharmaceutical partners and physicians."

Shawn Patrick O'Brien, Chief Executive Officer, commented, "Profectus BioSciences has a strong value proposition since the vaccine sector has emerged as a key revenue generator for big pharma with favorable legislation, relatively low development risk, exemplary commercial success of several blockbuster vaccines, and therapeutic vaccines being more attractive than preventative vaccines. By retaining LaVoie Group, I am confident that we will deliver our message more effectively to our key constituencies."

About Profectus BioSciences, Inc.

Profectus BioSciences is an innovative research and development vaccine company devoted to advancing the treatment and prevention of chronic viral diseases. The Profectus proprietary vaccine design approach combines its pDNA and rVSV platforms via a unique prime boost strategy to enhance immune response. Profectus' broad product pipeline will address Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), Human Papilloma Virus (HPV) and Herpes Simplex Virus (HSV).

The Profectus portfolio has received over $100 million in funding from multiple sources including National Institutes of Health (NIH), Cross Atlantic Capital Partners and through private investments. Profectus deploys these resources in support of its proprietary prime boost vaccines and its anti-inflammatory small molecules for cancer and chronic viral diseases. For more information, please visit: http://www.profectusbiosciences.com.

About LaVoie Group, Inc.

LaVoie Group provides senior-level strategic counsel and tactical implementation of venture, investor and public relations programs designed to properly position, create visibility and drive value for each client. We help our life sciences companies attract capital, reach corporate partners, generate revenue and build their companies through integrated communications programs. Our clients range from privately held start-ups to industry leaders in life sciences such as Vertex Pharmaceuticals, ESBATech AG, and Agile Therapeutics.

In March 2009, LaVoie Group was awarded the coveted 2008 Impact Award for "Best Industry-Exclusive Agency," sponsored by the League of American Communications Professionals (LACP). LaVoie Group is ranked by O'Dwyer's PR Report as one of the leading independent healthcare PR firms in the U.S. For more information, please visit http://www.lavoiegroup.com.


'/>"/>
SOURCE LaVoie Group
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. LaVoie Group Adds Bio-Surgery Company, Pegasus Biologics, to Its Life Sciences Agency Roster
2. Avicena Group to Present at Noble Financial Conference
3. Chrome Group to Seek Listing for Some of its Subsidiaries
4. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
5. Reed Group to Provide MDA Internet Disability Duration Guidelines to U.S. Navy
6. SportCoatings; The North American Booster Club Association (NABCA); the Coatings Specialist Group New Booster Program Goes High Tech With Invisible Antimicrobial Defense
7. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
8. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Completion of $2,277,000 Equity Financing
9. ThirdBiotech Networking Group Launches
10. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Appointment of Mark C. Mirken as its President and Chief Operating Officer
11. Reed Group Ltd. Announces Enterprise License for New Zealands Accident Compensation Corporation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... TX (PRWEB) , ... September ... ... LLC (IPS), a leading global provider of engineering, architecture, project controls, construction ... of prefabricated cleanrooms, today announced the unveiling of the iCON™ brand which ...
(Date:9/20/2017)... ... September 20, 2017 , ... Foresight Institute, a leading ... transformative technologies, announced the winners for the 2017 Foresight Institute Feynman Prizes.These are ... nanotechnology/molecular manufacturing. , Established in 1993 and named in honor of pioneer physicist ...
(Date:9/19/2017)... , ... September 19, 2017 , ... ... largest group of funded early-stage tech companies. “Grit” author Angela Duckworth and her ... joining the ic@3401 community is Cooley, an international law firm with decades of ...
(Date:9/19/2017)... 19, 2017 ValGenesis Inc., the global leader ... to announce the strategic partnership with VTI Life Sciences ... validation services using the latest technology available in the ... clients with efficient and cost-effective validation services using ValGenesis ... the ValGenesis VLMS system. ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
(Date:4/6/2017)... LONDON , April 6, 2017 ... Control, RFID, ANPR, Document Readers, by End-Use (Transportation & ... Energy Facility, Oil, Gas & Fossil Generation Facility, Nuclear ... Healthcare, Educational, Other) Are you looking for ... Authentication sector? ...
(Date:4/3/2017)...  Data captured by IsoCode, IsoPlexis Corporation,s ... statistically significant association between the potency of ... objective response of cancer patients post-treatment. The ... cancer patients will respond to CAR-T cell ... to improve both pre-infusion potency testing and cell ...
Breaking Biology News(10 mins):